|
1
|
Effect of clopidogrel on early failure of arteriovenous fistulas for hemodialysis: a randomized controlled trial.
|
JAMA
|
2008
|
7.50
|
|
2
|
Age affects outcomes in chronic kidney disease.
|
J Am Soc Nephrol
|
2007
|
5.36
|
|
3
|
Effect of homocysteine lowering on mortality and vascular disease in advanced chronic kidney disease and end-stage renal disease: a randomized controlled trial.
|
JAMA
|
2007
|
4.60
|
|
4
|
Effect of dipyridamole plus aspirin on hemodialysis graft patency.
|
N Engl J Med
|
2009
|
3.69
|
|
5
|
FGF-23 associates with death, cardiovascular events, and initiation of chronic dialysis.
|
J Am Soc Nephrol
|
2011
|
3.52
|
|
6
|
Current guidelines for using angiotensin-converting enzyme inhibitors and angiotensin II-receptor antagonists in chronic kidney disease: is the evidence base relevant to older adults?
|
Ann Intern Med
|
2009
|
1.98
|
|
7
|
Design of clinical trials in acute kidney injury: report from an NIDDK workshop on trial methodology.
|
Clin J Am Soc Nephrol
|
2012
|
1.90
|
|
8
|
Potential cost savings of erythropoietin administration in end-stage renal disease.
|
Am J Med
|
2002
|
1.83
|
|
9
|
Chronic kidney disease associated with environmental toxins and exposures.
|
Adv Chronic Kidney Dis
|
2010
|
1.60
|
|
10
|
High doses of epoetin do not lower mortality and cardiovascular risk among elderly hemodialysis patients with diabetes.
|
Kidney Int
|
2011
|
1.56
|
|
11
|
Change in use of gadolinium-enhanced magnetic resonance studies in kidney disease patients after US Food and Drug Administration warnings: a cross-sectional study of Veterans Affairs Health Care System data from 2005-2008.
|
Am J Kidney Dis
|
2010
|
1.52
|
|
12
|
Design of the Dialysis Access Consortium (DAC) Clopidogrel Prevention of Early AV Fistula Thrombosis Trial.
|
Clin Trials
|
2005
|
1.31
|
|
13
|
The Central American epidemic of CKD.
|
Clin J Am Soc Nephrol
|
2012
|
1.24
|
|
14
|
Design of clinical trials in acute kidney injury: a report from an NIDDK workshop--prevention trials.
|
Clin J Am Soc Nephrol
|
2012
|
1.20
|
|
15
|
Design of clinical trials in AKI: a report from an NIDDK workshop. Trials of patients with sepsis and in selected hospital settings.
|
Clin J Am Soc Nephrol
|
2012
|
1.13
|
|
16
|
Homocysteine lowering and cognition in CKD: the Veterans Affairs homocysteine study.
|
Am J Kidney Dis
|
2009
|
1.06
|
|
17
|
Associations of plasma 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D concentrations with death and progression to maintenance dialysis in patients with advanced kidney disease.
|
Am J Kidney Dis
|
2012
|
1.05
|
|
18
|
Randomized controlled trial of prophylactic repair of hemodialysis arteriovenous graft stenosis.
|
Kidney Int
|
2004
|
1.04
|
|
19
|
Whether and when to refer patients for predialysis AV fistula creation: complex decision making in the face of uncertainty.
|
Semin Dial
|
2010
|
1.03
|
|
20
|
Racial differences in markers of mineral metabolism in advanced chronic kidney disease.
|
Clin J Am Soc Nephrol
|
2012
|
1.03
|
|
21
|
Changes in kidney function among Nicaraguan sugarcane workers.
|
Int J Occup Environ Health
|
2015
|
0.99
|
|
22
|
Design of the Dialysis Access Consortium (DAC) Aggrenox Prevention Of Access Stenosis Trial.
|
Clin Trials
|
2005
|
0.96
|
|
23
|
Predialysis nephrology care and costs in elderly patients initiating dialysis.
|
Med Care
|
2011
|
0.94
|
|
24
|
Chronic kidney disease in Nicaragua: a qualitative analysis of semi-structured interviews with physicians and pharmacists.
|
BMC Public Health
|
2013
|
0.90
|
|
25
|
Predialysis nephrology care among older veterans using Department of Veterans Affairs or Medicare-covered services.
|
Am J Manag Care
|
2010
|
0.90
|
|
26
|
Validation of erythropoietin use data on Medicare's End-Stage Renal Disease Medical Evidence Report.
|
J Rehabil Res Dev
|
2010
|
0.84
|
|
27
|
Comparing VA and private sector healthcare costs for end-stage renal disease.
|
Med Care
|
2012
|
0.83
|
|
28
|
Adherence to guidelines for ESRD anemia management.
|
Am J Kidney Dis
|
2006
|
0.82
|
|
29
|
Medication adherence assessment in a clinical trial with centralized follow-up and direct-to-patient drug shipments.
|
Clin Trials
|
2011
|
0.81
|
|
30
|
Effect of the MTHFR C677T and A1298C polymorphisms on survival in patients with advanced CKD and ESRD: a prospective study.
|
Am J Kidney Dis
|
2009
|
0.81
|
|
31
|
Low body mass index and dyslipidemia in dialysis patients linked to elevated plasma fibroblast growth factor 23.
|
Am J Nephrol
|
2013
|
0.80
|
|
32
|
Higher fibroblast growth factor-23 concentrations associate with left ventricular systolic dysfunction in dialysis patients.
|
Clin Nephrol
|
2013
|
0.79
|
|
33
|
Value of static venous pressure for predicting arteriovenous graft thrombosis.
|
Kidney Int
|
2002
|
0.77
|
|
34
|
Racial differences in erythropoietin responsiveness.
|
Am J Kidney Dis
|
2008
|
0.77
|
|
35
|
25-hydroxyvitamin D deficiency is associated with an increased risk of metabolic syndrome in patients with non-diabetic chronic kidney disease.
|
Clin Nephrol
|
2012
|
0.75
|
|
36
|
Anemia management in CKD patients in the era of new US Food and Drug Administration recommendations on the use of erythropoiesis-stimulating agents.
|
Am J Kidney Dis
|
2013
|
0.75
|
|
37
|
Mineral Metabolites, Angiotensin II Inhibition and Outcomes in Advanced Chronic Kidney Disease.
|
Am J Nephrol
|
2015
|
0.75
|